The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Advances in CLL treatment
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, comments on potential developments in the field of chronic lymphocytic leukemia (CLL) research. Recent advances include the expansion of non-chemotherapy options such as Bruton’s tyrosine kinase (BTK) inhibitors and alternatives to lifelong, indefinite treatment regimens. The advent of minimal residual disease (MRD)-guided therapies has additionally made personalized therapies possible for patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
